NewAmsterdam Pharma Company N.V. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
References
Sources used in this report
SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-27 · Confirms NAMS ticker, listed issuer name, exchange and CIK where available.SEC APISEC submissions for NewAmsterdam Pharma Company N.V.Retrieved 2026-05-27 · Company identity, filing chronology, fiscal year end, SIC description, addresses and latest filing metadata.SEC XBRL APISEC companyfacts for NewAmsterdam Pharma Company N.V.Retrieved 2026-05-27 · XBRL-derived revenue, profit, cash-flow and balance-sheet cross-checks when tagged facts are available.10-KNewAmsterdam Pharma Company N.V. annual report2026-02-18 · annual report. Used for business description, risk factors, financial statement context, governance chronology or recent event review.10-QNewAmsterdam Pharma Company N.V. latest quarterly or interim report2026-05-07 · latest quarterly or interim report. Used for business description, risk factors, financial statement context, governance chronology or recent event review.8-KNewAmsterdam Pharma Company N.V. current report2026-05-07 · current report. Used for business description, risk factors, financial statement context, governance chronology or recent event review.DEF 14ANewAmsterdam Pharma Company N.V. proxy statement2026-05-06 · proxy statement. Used for business description, risk factors, financial statement context, governance chronology or recent event review.